Evaluating the quality of real-world evidence with a standardized assessment tool: an interview with Ashley Jaksa and Katsiaryna Bykov

Barriers to using real-world evidence (RWE) studies on drug effectiveness and safety by decision makers often results from lack of consensus on the evaluation of the quality and validity of these studies. Several tools are available to assess RWE studies for bias but are often lacking. To address the need to enhance the quality of RWE assessment, an International Society for Pharmacoepidemiology (ISPE)-led group created an assessment tool to aid health technology assessment (HTA) bodies and payer decision makers in evaluating RWE studies. In the recent ISPOR 2023 Workshop ‘Standardized Assessment Tool Designed to Assist in Evaluation of RWE on...